Nicholas Lydon
Nicholas B. Lydon FRS is a British scientist and entrepreneur. In 2009, he was awarded the Lasker Clinical Award and in 2012 the Japan Prize for the development of Gleevec, also known as Imatinib, a selective BCR-ABL inhibitor for the treatment of chronic myeloid leukaemia (CML), which converted a fatal cancer into a manageable chronic condition.
From *.wikipedia.org,
Información General
.
Hombre
Fecha de nacimiento
27 de febrero, 1957
Edad
69
Zodíaco
Piscis
Redes sociales , Enlaces
Interés
Loading Chart...
Listas